Fig 1.
Phenotype comparison between G3 and G5 of JEV.
(A) CPE of BHK-21 cells caused by P3 and XZ0934 strains at different times, included rounding, and cell rupture. (B) Plaque phenotype of the JEV P3 and XZ0934 strains in BHK-21 cells after 3 days of infection. (C) Relative multiplication characteristics of the P3 and XZ0934 strains in BHK-21 cells. Cells were plated into 6-well culture plates and infected with the JEV strains at a MOI of 0.01pfu /cell. Values represent the mean and standard deviation from three independent experiments.
Table 1.
Phenotypic characteristics of G5 and G3 JEV.
Fig 2.
Protection against i.p. challenge with different JE virus strains.
Groups of 10 4-week-old mice were immunized with either (A) 10−3 (2510 pfu), 10−4 (251 pfu) or 10−5 (25 pfu) live attenuated vaccine (LAV) or with (B) 1:5, 1:25 or 1:125 dilutions of inactivated purified vaccine (IPV). Then all mice were challenged i.p. with 500 LD50 JEV P3 or XZ0934 strains.
Fig 3.
SA14-14-2 JE LAV–induced immune response in two-year-old children 28 days before and after vaccination.
PRNT90 titers against viral strains of different JEV genotypes are shown before and 28 days after a vaccination: (A) G1 JEV (GZ56 strain), (B) G3 JEV (P3 strain) and (C) G5 JEV (XZ0934 strain). (D) end-point PRNT90 titers against three genotypes JEV antibodies were assayed. The gray lines indicate PRNT90 titer = 1:10. PRNT90 titers of ≥1:10 were considered protective. The seroconversion rates (SCRs) and geometric mean titers (GMTs) are given in each panel. P < 0.05 showed statistically significant.
Table 2.
Strain-specific protection threshold of Japanese encephalitis virus vaccine.
Table 3.
The neutralizing antibody response against different genotype JEV in serum of acute phase from clinical JE patients in different ages.